Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids)
Patents for A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids) (127,169)
06/2003
06/03/2003CA2047858C (quinolin-2-ylmethoxy)tetrahydrocarbazoles as inhibitors of the biosynthesis of leukotrienes
05/2003
05/30/2003WO2003044172A2 Composition comprising and method of using angiopoietin-like protein 3 angptl3
05/30/2003WO2003044170A2 Cyclic amp phosphodiesterase 4d7 isoforms and methods of use
05/30/2003WO2003044053A2 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
05/30/2003WO2003044031A1 Technetium or rhenium complexes, radiopharmaceutical products comprising them
05/30/2003WO2003044023A1 The use of anti-histaminics for acute reduction of elevated intracranial pressure
05/30/2003WO2003044021A2 Substituted indolizine-like compounds and methods of use
05/30/2003WO2003044014A1 Indole-2-carboxamides as factor xa inhibitors
05/30/2003WO2003044010A1 Nitrogenous tetrahydropyridyl-alkyl-heterocycles with tnf activity
05/30/2003WO2003044009A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
05/30/2003WO2003044000A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
05/30/2003WO2003043988A1 Piperidin-2-one derivative compounds and drugs containing these compounds as the active ingredient
05/30/2003WO2003043985A1 Heterocyclic compounds and methods of use
05/30/2003WO2003043981A1 2-(3-sulfonylamino-2-oxopyrrolidin-1-yl)propanamides as factor xa inhibitors
05/30/2003WO2003043905A2 Pharmaceutical product with an adsorbent
05/30/2003WO2003043657A1 Topical delivery of codrugs
05/30/2003WO2003043644A1 Ulcerative-colitis therapeutic agent containing iron salt as active ingredient
05/30/2003WO2003043636A1 Nicotin-or isonicotin benzothiazole derivatives
05/30/2003WO2003043629A1 Medicine based on diethylaminoethanol derivatives and its use for the prevention and treatment of inflammatory and degenerative diseases
05/30/2003WO2003043625A1 2-aryl-propionic acids and pharmaceutical compositions containing them
05/30/2003WO2003043621A1 Pharmaceutical and cosmetic compositions containing oxy group-bearing aromatic aldehydes
05/30/2003WO2003043617A1 Compositions and kits comprising a defined boron compound, methods of their preparation, and use and administration thereof
05/30/2003WO2003043613A2 Use of glycosides of mono- and diacylglycerol as anti-inflammatory agents
05/30/2003WO2003043604A1 Method for preparing a compound for interaction of active substances with a porous support using supercritical fluid
05/30/2003WO2003043583A2 Treatment of immunological disorders using anti-cd30 antibodies
05/30/2003WO2003043518A2 Methods and products for oral care
05/30/2003WO2003020104A3 Method of treating systemic inflammatory response syndrome
05/30/2003WO2003016917A3 Sodium channel regulators and modulators
05/30/2003WO2002100328A3 Treating pain by targeting hyperpolarization-activated, cyclic nucleotide-gated channels
05/30/2003WO2002096952A3 Conjugate of a transport protein and a protein for modulation of notch signalling
05/30/2003WO2002096363A3 Method for treating fibrotic diseases or other indications
05/30/2003WO2002070509A3 Antagonists of mcp-1 function and methods of use thereof
05/30/2003WO2002067967A3 Method of treating rhinitis or sinusitis
05/30/2003WO2002029091A3 Methods and compositions for the treatment of inflammatory diseases
05/30/2003WO2002020090A3 Pharmaceutical compositions
05/30/2003WO2002016313A3 Integrin receptor inhibitors
05/30/2003WO2002000692A9 Pd-l2 molecules: pd-1 ligands and uses therefor
05/30/2003WO2001091792A3 Anti-adhesion molecule antibody to treat inflammation and cancer by inducing the idiotypic network
05/30/2003WO2001080823A3 Composition exhibiting enhanced formulation stability and delivery of tropical active ingredients
05/30/2003CA2467752A1 Piperidin-2-one derivative compounds and pharmaceutical composition comprising the same as active ingredient
05/30/2003CA2467747A1 Methods and products for oral care
05/30/2003CA2467559A1 Topical delivery of codrugs
05/30/2003CA2467242A1 Treatment of immunological disorders using anti-cd30 antibodies
05/30/2003CA2467053A1 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
05/30/2003CA2467035A1 Pharmaceutical product with an adsorbent
05/30/2003CA2466733A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
05/30/2003CA2466491A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
05/30/2003CA2466072A1 Substituted indolizine-like compounds and methods of use
05/30/2003CA2464867A1 Pharmaceutical and cosmetic compositions containing oxy group-bearing aromatic aldehydes
05/30/2003CA2464542A1 Composition comprising and method of using angiopoietin-like protein 3 angptl3
05/30/2003CA2463790A1 Cyclic amp phosphodiesterase 4d7 isoforms and methods of use
05/29/2003US20030100772 Oxygen-containing heterocyclic compounds
05/29/2003US20030100765 Process for preparing heterocyclo-alkysulfonyl pyrazole derivatives
05/29/2003US20030100608 1,4-disubstituted benzo-fused cycloalkyl urea compounds
05/29/2003US20030100607 Thiolalkyl benzoic acid derivatives
05/29/2003US20030100603 Administering to the patient subject to a C-reactive protein associated inflammatory condition, an effective amount of a non-alpha-tocopherol enriched tocopherol
05/29/2003US20030100599 2-amino-fluorene derivatives useful for prophylactic and/or therapeutic treatment of diseases and conditions associated with alpha 4 intergrins or their ligands
05/29/2003US20030100595 Oral dosage form of a sulfonamide prodrug
05/29/2003US20030100594 Carbonic anhydrase inhibitor
05/29/2003US20030100588 Indole-type inhibitors of p38 kinase
05/29/2003US20030100585 For example 3-(2-(1-(2-(3-Methoxy-4-(3-o-tolyl-ureido)-phenyl)-acetylamino )- 3-methyl-butyl)-4,5-dihydro-oxazol-5-yl)-2-methyl-propionic acid
05/29/2003US20030100571 Such as 2-((6-(((4-(3,4-dimethoxyphenyl)methyl)amino)-7-ethyl-7H-purin-2-yl)amino) -4,5-methyl-N-phenyl-5-thiazole-carboxamide for treatment of lymphocyte mediated diseases such as transplant rejection and graft versus host disease
05/29/2003US20030100570 Immunomodulation and effect on cell processes relating to serotonin family receptors
05/29/2003US20030100567 Tyrosine kinase inhibitors
05/29/2003US20030100558 Such as 4-(4-fluorophenyl)-5-(2-phenylmethylamino)pyrimidin-4-yl)-1-ethoxymethyl -(1,2,3)triazole for inhibition of release of inflammatory interleukins; for treatment of osteoarthritis, rheumatoid arthritis, and congestive heart failure
05/29/2003US20030100556 Such as (S)-N-(5-(4-Methylpiperazin-1-yl)-3,4-dihydro-2H-1-benzopyran-3-yl)-4 -morpholinobenzamide for treatment of mood/anxiety/eating disorders
05/29/2003US20030100538 Substituted chalcones as therapeutic compounds
05/29/2003US20030100516 Analgesic agent
05/29/2003US20030100510 Crystallized structure of type IV collagen NC1 domain hexamer
05/29/2003US20030100486 Inflammatory markers as tools in the detection and prevention of diabetes mellitus and as tools to aid in the selection of agents to be used for the prevention and treatment of diabetes
05/29/2003US20030099991 Detection of nucleotide sequences associated pain and nervous system disorders; obtain sample, incubate with probe, detect signal, recover nucleic acid, incubate with primer, amplify, evaluate for disorder
05/29/2003US20030099765 Process for coating a surface of a stent
05/29/2003US20030099747 Thickened oil compositions of edible oil
05/29/2003US20030099732 Proteoglycan Compositions for Treating Prostate and Bladder Inflammatory Conditions
05/29/2003US20030099730 Nutritional supplement and methods of using it
05/29/2003US20030099725 For therapy and prophylaxis of cancers especially cancer of lung, esophagus, stomach, oral cavity and prostate as well as for therapy of Helicobacter pylori infection; useful as adjuncts to conventional surgery or radiotherapy
05/29/2003US20030099718 Nanocrystalline antimicrobial metals (noble metals)formed with atomic disorder are capable of releasing highly active clusters of the antimicrobial metal sufficient to cause microbiocidal effect; anti-inflammatory activity
05/29/2003US20030099694 Method for the improvement of transport across adaptable semi-permeable barriers
05/29/2003US20030099666 Gum resin as a carrier for topical application of pharmacologically active agents
05/29/2003US20030099661 Compositions and methods for the treatment of immune related diseases
05/29/2003US20030099652 Novel human protein tyrosine kinase
05/29/2003US20030099608 Human cytokine receptor
05/28/2003EP1314733A1 Indole-2-carboxamides as factor Xa inhibitors
05/28/2003EP1314732A2 Substituted pyrimidine compounds and their use
05/28/2003EP1314731A2 Substituted pyrimidine compounds and their use
05/28/2003EP1314728A1 Pyridyl and pyrimidinyl imines as intermediates for imidazole derivatives
05/28/2003EP1314721A1 Novel propenohydroxamic acid derivatives
05/28/2003EP1314719A1 Benzoic acid derivatives and drugs containing the same as the active ingredient
05/28/2003EP1314426A1 Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases
05/28/2003EP1313857A2 Lipid metabolism molecules
05/28/2003EP1313853A2 Modulation of fas and fasl expression
05/28/2003EP1313844A2 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
05/28/2003EP1313843A2 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
05/28/2003EP1313772A1 New cross-linked derivatives of hyaluronic acid
05/28/2003EP1313769A2 Antibodies to human il-1 beta
05/28/2003EP1313768A2 Antisense oligonucleotides against vr1
05/28/2003EP1313737A1 Novel guanidino derivatives as inhibitors of cell adhesion
05/28/2003EP1313730A1 Pyrrolidine derivatives and their use as chymase inhibitor
05/28/2003EP1313728A1 Substituted pyrimidines as selective cyclooxygenase-2 inhibitors
05/28/2003EP1313726A1 Quinoline derivatives having vegf inhibiting activity
1 ... 839 840 841 842 843 844 845 846 847 848 849 850 851 852 853 854 855 856 857 858 859 ... 1272